##ANALYSISTYPE=SOMATIC_SINGLESAMPLE
##PIPELINE=megSAP 2024_09-249-gdc237d73
##GENOME_BUILD=GRCh38
##CREATION_DATE=2025-03-11
##FILTER=indelError=Likely artifact due to indel reads at this position
##FILTER=low_conf_region=Variant marked as 'low_conf_region'.
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=str10=Less than 10% or more than 90% of variant supporting reads on one strand
##SAMPLE=<ID=DX000001_01,IsTumor=yes>
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), quality divided by depth (QD), allele frequency (AF), mean mapping quality of alternate allele (MQM), probability of strand bias for alternate bases as phred score (SAP), probability of allele ballance as phred score (ABP)
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous/hemizygous case count of gnomAD project (genome data).
##DESCRIPTION=gnomAD_het=Heterozygous allele count of the gnomAD project (genome data).
##DESCRIPTION=gnomAD_wt=Wildtype allele count of the gnomAD project (genome data).
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=AlphaMissense=AlphaMissense pathogenicity score. Deleterious threshold > 0.564.
##DESCRIPTION=MaxEntScan=MaxEntScan reference score and alternate score for (1) native splice site, (2) acceptor gain and (3) donor gain. Comma-separated list if there are different predictions for several transcripts.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=SpliceAI=SpliceAI prediction. These include delta scores (DS) and delta positions (DP) for acceptor gain (AG), acceptor loss (AL), donor gain (DG), and donor loss (DL). Format: GENE|DS_AG|DS_AL|DS_DG|DS_DL|DP_AG|DP_AL|DP_DG|DP_DL.
##DESCRIPTION=PubMed=PubMed ids to publications on the given variant.
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD (tumor-normal).
##DESCRIPTION=NGSD_som_p=Project names containing this somatic variant in the NGSD (tumor-normal).
##DESCRIPTION=NGSD_som_to_c=Somatic variant count in the NGSD (tumor-only).
##DESCRIPTION=NGSD_som_vicc_interpretation=Somatic variant interpretation according VICC standard in the NGSD.
##DESCRIPTION=NGSD_som_vicc_comment=Somatic VICC interpretation comment in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_mosaic=Mosaic variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##DESCRIPTION=CMC_genes=Gene symbol from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_MUTATION_ID=COSV identifier of variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_disease=diseases with > 1% of samples mutated where disease = Primary site(tissue) / Primary histology / Sub-histology = Samples mutated / Samples tested = Frequency from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_DNDS_ratio=diseases with significant dn/ds ratio (q-value < 5%) from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_mutation_significance=Significance tier of the variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CANCERHOTSPOTS_AA_CHANGE=Amino acid change as in original cancerhotspots.org file
##DESCRIPTION=CANCERHOTSPOTS_TOTAL_MUT=Total mutation count in cancerhotspots.org at certain amino acid position.
##DESCRIPTION=CANCERHOTSPOTS_ALT_COUNT=Count of specific amino acid alteration at same position in cancerhotspots.org.
##FILTER=low_conf_region=Low confidence region for small variant calling based on gnomAD AC0/RF filters and IMGAG trio/twin data.
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample DX000001_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample DX000001_01).
##DESCRIPTION=somatic_classification_comment=Somatic classification comment from the NGSD.
##DESCRIPTION=somatic_classification=Somatic classification from the NGSD.
##DESCRIPTION=ncg_oncogene=1:gene is oncogene according NCG7.1, 0:No oncogene according NCG7.1, na: no information available about gene in NCG7.1. Order is the same as in column gene.
##DESCRIPTION=ncg_tsg=1:gene is TSG according NCG7.1, 0:No TSG according NCG7.1, na: no information available about gene in NCG7.1. Order is the same as in column gene.
#chr	start	end	ref	obs	tumor_af	tumor_dp	filter	quality	gene	variant_type	coding_and_splicing	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	gnomAD	gnomAD_sub	gnomAD_hom_hemi	gnomAD_het	gnomAD_wt	phyloP	CADD	REVEL	AlphaMissense	MaxEntScan	COSMIC	SpliceAI	PubMed	NGSD_som_c	NGSD_som_p	NGSD_som_to_c	NGSD_som_vicc_interpretation	NGSD_som_vicc_comment	NGSD_hom	NGSD_het	NGSD_mosaic	NGSD_group	classification	classification_comment	somatic_classification	somatic_classification_comment	validation	comment	gene_info	CMC_genes	CMC_MUTATION_ID	CMC_disease	CMC_DNDS_ratio	CMC_mutation_significance	CANCERHOTSPOTS_AA_CHANGE	CANCERHOTSPOTS_TOTAL_MUT	CANCERHOTSPOTS_ALT_COUNT	ncg_oncogene	ncg_tsg
chr7	140734774	140734774	-	A	0.1327	113	low_conf_region	QUAL=47	BRAF	splice_region&intron	BRAF:ENST00000496384.7:splice_region_variant&intron_variant:LOW:intron17/18:c.2128-5dup::,BRAF:ENST00000644969.2:splice_region_variant&intron_variant:LOW:intron18/19:c.2248-5dup::,BRAF:ENST00000646891.2:splice_region_variant&intron_variant:LOW:intron17/17:c.2128-5dup::,BRAF:ENST00000288602.11:splice_region_variant&intron_variant:LOW:intron18/18:c.2248-5dup::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	44820 [likely benign(replaced by megSAP based on classifications:5x1,3x3) DISEASE=not provided,Noonan syndrome with multiple lentigines,Noonan syndrome,not specified,RASopathy,Congenital long QT syndrome,Noonan syndrome and Noonan-related syndrome,Cardio-facio-cutaneous syndrome GENE=BRAF];			rs373442098	0.24546	0.11735,0.21429,0.25281,0.30325,0.26531	194,	5527	18183		7.23			/11.6>11.3/0.0>0.0		BRAF|0.00|0.00|0.00|0.00|-4|18|36|37		1	SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	2	"[2] auto-classification 16.09.2017  "					BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140749271	140749271	C	G	0.9962	262	low_conf_region	QUAL=255	BRAF	splice_region&intron	BRAF:ENST00000496384.7:splice_region_variant&intron_variant:LOW:intron16/18:c.1992+16G>C::,BRAF:ENST00000644969.2:splice_region_variant&intron_variant:LOW:intron17/19:c.2112+16G>C::,BRAF:ENST00000646891.2:splice_region_variant&intron_variant:LOW:intron16/17:c.1992+16G>C::,BRAF:ENST00000288602.11:splice_region_variant&intron_variant:LOW:intron17/18:c.2112+16G>C::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40393 [benign/likely benign DISEASE=RASopathy,not provided,Cardiofaciocutaneous syndrome 1,Melanoma, cutaneous malignant, susceptibility to, 1,Noonan syndrome 1,LEOPARD syndrome 3,Noonan syndrome 7,Colorectal cancer,Lung cancer,not specified GENE=BRAF];			rs3789806	0.29855	0.66471,0.18034,0.17415,0.14178,0.30884	10808,	23762	106616	0.3130	11.88			/0.9>1.3/0.0>0.0	COSV56062530	BRAF|0.00|0.00|0.00|0.00|-33|22|16|17	25741868,24033266,23757202,34482832,27779249,24920063	8	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140749350	140749350	T	C	0.9975	398		QUAL=255	BRAF	synonymous	BRAF:ENST00000496384.7:synonymous_variant:LOW:exon16/19:c.1929A>G:p.Gly643=:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000644969.2:synonymous_variant:LOW:exon17/20:c.2049A>G:p.Gly683=:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000646891.2:synonymous_variant:LOW:exon16/18:c.1929A>G:p.Gly643=:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000288602.11:synonymous_variant:LOW:exon17/19:c.2049A>G:p.Gly683=:PF07714 [Protein tyrosine and serine/threonine kinase]		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40391 [benign DISEASE=not provided,not specified,Noonan syndrome 7,LEOPARD syndrome 3,RASopathy,Cardiovascular phenotype GENE=BRAF];			rs9648696	0.30118	0.66933,0.18289,0.17531,0.14367,0.31198	10970,	23846	106236	1.5810	7.94	0.247		/0.0>0.0/0.0>0.0	COSV56058907	BRAF|0.00|0.00|0.00|0.00|-31|1|-8|-3	25741868,24033266,23757202,26559640,18060073,34482832	9	ARO-16,Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)	BRAF	COSV56058907	soft_tissue/haemangioblastoma/NS=7/25=28%		Other				1	0
chr7	140753336	140753336	A	T	0.3566	1646		QUAL=255	BRAF	missense	BRAF:ENST00000496384.7:missense_variant:MODERATE:exon15/19:c.1799T>A:p.Val600Glu:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000644969.2:missense_variant:MODERATE:exon16/20:c.1919T>A:p.Val640Glu:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000646891.2:missense_variant:MODERATE:exon15/18:c.1799T>A:p.Val600Glu:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000288602.11:missense_variant:MODERATE:exon16/19:c.1919T>A:p.Val640Glu:PF07714 [Protein tyrosine and serine/threonine kinase]		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	13961 [pathogenic/likely pathogenic DISEASE=Nephroblastoma,Nongerminomatous germ cell tumor,not provided,Cerebral arteriovenous malformation,Carcinoma of colon,Malignant neoplastic disease,Cardio-facio-cutaneous syndrome,Astrocytoma, low-grade, somatic,Vascular malformation,Lymphangioma,Papillary thyroid carcinoma,Melanoma,Multiple myeloma,Non-small cell lung carcinoma,Cystic epithelial invagination containing papillae lined by columnar epithelium,Cardiovascular phenotype GENE=BRAF];	CM2120436 [CLASS=R MUT=ALT PHEN="Ocular juvenile xanthogranuloma" GENE=BRAF];		rs113488022						9.2360	29.80	0.931	0.99	/0.0>0.0/0.0>0.0	COSV56056643,COSV56065204,COSV56080151	BRAF|0.00|0.00|0.00|0.00|6|22|-14|32	23757202,30089490,26900293,12460918,20619739,21107323,22773810,23614898,25032700,25157968,26619011,24144365,31752122,12960123,12068308,12460919,14679157,15035987,19001320,19010912,19018267,19238210,19404918,19537845,19561230,20350999,20413299,20630094,20735442,20818844,21129611,21156289,21163703,21426297,21483012,21639808,21683865,21975775,22038996,22048237,22180495,22281684,22351686,22356324,22389471,22448344,22536370,22586120,22608338,22649091,22663011,22735384,22743296,22805292,22972589,22997239,23020132,23031422,23251002,23325582,23470635,23524406,23549875,23812671,23833300,23845441,23918947,24107445,24163374,24388723,24576830,24583796,24586605,24594804,25024077,25370471,25989278,26678033,12198537,21107320,33076847,32184228,26090869,32843432,32238401,26310374,28607096,35311178,31371350,30770838,26513174,28556791,32933095,24512911,32770181,36733350,28708103,28282860,35904569,35820816,30797065,26909593,34667063,36866106,36686473,29043205,35582142,25950823,24670642,15001635,31891627,34476331,15356022,2330280	416	20101I_0461_Stephan,ARO-16,AxelMelanomaPhD,DNPM-WES,Novartis,Siena_1328_Mel_WES,SomaticAndTreatment,Test_Twist_Exome_Covaris,WES_Onko_test,WES_ZPM,practical_training	0	ONCOGENIC	inframe delins "BRAF: c.1799_1800delinsTT" detected in ~60% of somatic genome reads Somatic variant encoded by codon600 is altered from Valine to Lysine: BRAF p.V600K  For Your Information: Other Known Oncogenic Protein Variants encoded by this codon as per COSMIC Recurrence Data are  BRAF p.V600E BRAF p.V600M BRAF p.V600A BRAF p.V600R BRAF p.V600G BRAF p.V600D BRAF p.V600L BRAF p.V600delinsYM 	0	5	3	0 / 0		"[import GPD] Christopher Schroeder 2013-05-07 09:14:08 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/21663470?dopt=Abstract&holding=npg -doi: 10.1056/NEJMoa1014209 BRAF mutations in hairy-cell leukemia.  [import GPD] Christopher Schroeder 2013-05-07 09:14:45 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/22210875?dopt=Abstract&holding=npg -doi: 10.1182/blood-2011-09-379339 Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.  [import GPD] Christopher Schroeder 2013-05-02 17:26:11 -type: lit / druggable -link: http://www.nejm.org/doi/full/10.1056/NEJMc1215697?query=TOC -drugs: vemurafenib BRAF V600E Inhibition in Anaplastic Thyroid Cancer  [import GPD] Christopher Schroeder 2013-05-07 18:21:28 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/22395615?dopt=Abstract&holding=npg -doi: 10.1038/ncomms1727 Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.  [import GPD] Christopher Schroeder 2013-05-15 11:43:10 -type: lit / preclinical study -link: http://www.nature.com/nature/journal/v483/n7387/full/nature10868.html -doi: 10.1038/nature10868 -drugs: vemurafenib, cetuximab, gefitinib, panitumumab Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.  => Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8–10% of all colon cancers2, 3, 5), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.  [import GPD] Christopher Schroeder 2013-05-03 17:12:18 -type: lit / druggable -link: http://www.nejm.org/doi/full/10.1056/NEJMoa1103782 -drugs: vemurafenib Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation  [import GPD] Christopher Schroeder 2013-05-28 15:50:19 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/20818844 -doi: 10.1056/NEJMoa1002011 -drugs: vemurafenib Inhibition of mutated, activated BRAF in metastatic melanoma. => Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.  [import GPD] Christopher Schroeder 2013-06-05 15:32:18 -type: lit / druggable -link: http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.45.7739?papetoc -doi: 10.1200/JCO.2012.45.7739 -drugs: vemurafenib Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation  [import GPD] Christopher Schroeder 2013-09-04 10:29:28 -type: lit / preclinical study -link: http://www.ncbi.nlm.nih.gov/pubmed/18676837 -doi: 10.1158/0008-5472.CAN-08-1430 -drugs: selumetinib, Trametinib Tumors harboring BRAF V600E mutations lack this negative feedback loop and are sensitive to MEK inhibitors.  [import GPD] Christopher Schroeder 2013-12-22 15:16:45 -type: lit / clinical trial -link: http://jco.ascopubs.org/content/31/35/e448?cmpid=jco_etoc_10December2013 -doi: 10.1200/JCO.2013.50.4118 -drugs: dabrafenib, Trametinib BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition => First, caution must be exercised when using BRAFis in patients or populations that might harbor RAS-mutated cells, be they in skin, bowel, or other sites.  [import GPD] Christopher Schroeder 2013-06-05 15:27:37 -type: case report -link: http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.47.6143?papetoc -doi: 10.1200/JCO.2012.47.6143 -drugs: vemurafenib, radiation Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma. Radiosensitizing effect of vemurafenib ("should probably not be combined with radiation")."	activating	[activating] aharmes1 03.04.2020		"PMID: 22614711  Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region."	BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)	BRAF	COSV56056643	NS/benign_melanocytic_nevus/congenital=4/14=28.57%;NS/carcinoma/of_unknown_primary=7/285=2.46%;NS/malignant_melanoma/NS=1047/3735=28.03%;adrenal_gland/adrenal_cortical_carcinoma/NS=4/300=1.33%;biliary_tract/carcinoma/adenocarcinoma=28/2217=1.26%;bone/other/ameloblastoma=27/97=27.84%;central_nervous_system/glioma/NS=24/1170=2.05%;central_nervous_system/glioma/astrocytoma=86/264=32.58%;central_nervous_system/glioma/astrocytoma_Grade_I=46/1152=3.99%;central_nervous_system/glioma/astrocytoma_Grade_II=50/409=12.22%;central_nervous_system/glioma/astrocytoma_Grade_III=36/482=7.47%;central_nervous_system/glioma/astrocytoma_Grade_IV=78/3173=2.46%;central_nervous_system/glioma/oligodendroglioma_Grade_II=5/150=3.33%;central_nervous_system/other/dysembryoplastic_neuroepithelial_tumour=26/87=29.89%;central_nervous_system/other/ganglioglioma=68/413=16.46%;central_nervous_system/primitive_neuroectodermal_tumour-medulloblastoma/NS=5/446=1.12%;eye/benign_melanocytic_nevus/NS=14/56=25%;eye/malignant_melanoma/NS=50/1274=3.92%;eye/malignant_melanoma/epithelioid=4/12=33.33%;eye/malignant_melanoma/mixed=8/59=13.56%;eye/malignant_melanoma/spindle=16/57=28.07%;eye/other/neoplasm_of_the_pigmented_ciliary_epithelium=4/5=80%;haematopoietic_and_lymphoid_tissue/lymphoid_neoplasm/Langerhans_cell_histiocytosis=149/985=15.13%;haematopoietic_and_lymphoid_tissue/lymphoid_neoplasm/follicular_dendritic_cell_sarcoma=5/50=10%;haematopoietic_and_lymphoid_tissue/lymphoid_neoplasm/hairy_cell_leukaemia=697/997=69.91%;haematopoietic_and_lymphoid_tissue/lymphoid_neoplasm/juvenile_xanthogranuloma=6/173=3.47%;haematopoietic_and_lymphoid_tissue/lymphoid_neoplasm/malignant_histiocytosis=6/15=40%;kidney/other/adenoma=31/72=43.06%;large_intestine/aberrant_crypt_foci/hyperplastic=11/230=4.78%;large_intestine/adenoma/NS=61/2850=2.14%;large_intestine/adenoma/tubular=13/1291=1.01%;large_intestine/adenoma/villous=8/89=8.99%;large_intestine/carcinoma/adenocarcinoma=4476/84708=5.28%;large_intestine/carcinoma/neuroendocrine_carcinoma=6/77=7.79%;large_intestine/carcinoma/serrated_carcinoma=4/152=2.63%;large_intestine/serrated_polyp/NS=13/236=5.51%;large_intestine/serrated_polyp/admixed_hyperplastic_polyp-adenoma=31/61=50.82%;large_intestine/serrated_polyp/hyperplastic_polyp=243/2245=10.82%;large_intestine/serrated_polyp/serrated_adenoma=579/2066=28.03%;large_intestine/serrated_polyp/serrated_fibroblastic_polyp-intramucosal_perineurioma=17/61=27.87%;ovary/adenoma/serous=14/144=9.72%;ovary/carcinoma/endometrioid_carcinoma=7/334=2.1%;ovary/carcinoma/mucinous_carcinoma=21/470=4.47%;ovary/carcinoma/serous_carcinoma=28/2260=1.24%;ovary/carcinoma/serous_micropapillary_carcinoma=17/43=39.53%;ovary/low_malignant_potential_(borderline)_tumour/NS=4/37=10.81%;ovary/low_malignant_potential_(borderline)_tumour/mucinous=4/229=1.75%;ovary/low_malignant_potential_(borderline)_tumour/serous=178/623=28.57%;ovary/other/neoplasm=4/66=6.06%;pancreas/carcinoid-endocrine_tumour/NS=7/167=4.19%;pituitary/craniopharyngioma/papillary=88/124=70.97%;salivary_gland/carcinoma/salivary_duct_carcinoma=6/161=3.73%;salivary_gland/other/sialadenoma_papilliferum=11/26=42.31%;skin/adnexal_tumour/other=4/15=26.67%;skin/adnexal_tumour/syringocystadenoma_papilliferum=17/40=42.5%;skin/benign_melanocytic_nevus/NS=251/632=39.72%;skin/benign_melanocytic_nevus/Spitz=12/453=2.65%;skin/benign_melanocytic_nevus/compound=187/315=59.37%;skin/benign_melanocytic_nevus/congenital=22/165=13.33%;skin/benign_melanocytic_nevus/dysplastic=61/192=31.77%;skin/benign_melanocytic_nevus/intradermal=323/537=60.15%;skin/benign_melanocytic_nevus/junctional=30/85=35.29%;skin/carcinoma/NS=4/103=3.88%;skin/lentigo/NS=5/100=5%;skin/malignant_melanoma/NS=4593/20734=22.15%;skin/malignant_melanoma/acral_lentiginous=100/1089=9.18%;skin/malignant_melanoma/desmoplastic=5/163=3.07%;skin/malignant_melanoma/in_situ_melanotic_neoplasm=24/129=18.6%;skin/malignant_melanoma/lentigo_maligna=18/171=10.53%;skin/malignant_melanoma/nodular=197/901=21.86%;skin/malignant_melanoma/radial_growth_phase=5/31=16.13%;skin/malignant_melanoma/spitzoid=5/209=2.39%;skin/malignant_melanoma/superficial_spreading=313/1291=24.24%;skin/malignant_melanoma/vertical_growth_phase=85/253=33.6%;skin/other/atypical_Spitzoid_tumour=20/111=18.02%;small_intestine/carcinoma/adenocarcinoma=8/386=2.07%;soft_tissue/desmoid_tumour-fibromatosis/NS=5/256=1.95%;soft_tissue/gastrointestinal_stromal_tumour/spindle=13/165=7.88%;soft_tissue/haemangioma/capillary=11/184=5.98%;testis/germ_cell_tumour/mixed=6/236=2.54%;testis/low_malignant_potential_(borderline)_tumour/serous=7/11=63.64%;thyroid/adenoma-nodule-goitre/NS=261/9059=2.88%;thyroid/carcinoma/NS=577/1388=41.57%;thyroid/carcinoma/anaplastic_carcinoma=240/1035=23.19%;thyroid/carcinoma/medullary_carcinoma=32/691=4.63%;thyroid/carcinoma/mixed_papillary_and_follicular_carcinoma=67/144=46.53%;thyroid/carcinoma/papillary_carcinoma=13758/44918=30.63%;thyroid/carcinoma/poorly_differentiated_carcinoma=63/495=12.73%;thyroid/chronic_thyroiditis/Hashimotos_thyroiditis=4/260=1.54%;thyroid/other/neoplasm=14/107=13.08%;urinary_tract/carcinoma/adenocarcinoma=4/125=3.2%	NSCLC=7.18e-16;colon=1.1e-123;glioma=4.37e-15;melanoma=0.0;thyroid=0.0	1				1	0
chr7	140777136	140777136	G	A	0.4303	165	off-target	QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron12/18:c.1518-48C>T::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron13/19:c.1638-48C>T::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron12/17:c.1518-48C>T::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron13/18:c.1638-48C>T::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40378 [benign DISEASE=not provided,not specified GENE=BRAF];			rs62487918	0.05677	0.02262,0.05308,0.08466,0.06938,0.11462	289,	8046	143294	-0.0310	7.63			/0.0>0.0/0.0>0.0	COSV56078557	BRAF|0.00|0.00|0.00|0.00|-48|-6|11|-4	25741868	3	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140782627	140782627	T	C	0.6230	244		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron10/18:c.1314+394A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron11/19:c.1434+394A>G::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron10/17:c.1314+394A>G::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron11/18:c.1434+394A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L1PA8 (LINE/L1)	rs1267642	0.09761	0.14627,0.06883,0.08979,0.06969,0.19105	785,	13290	137374	-0.1040	1.26			/0.0>0.0/5.5>1.4	COSV56180912	BRAF|0.00|0.00|0.00|0.00|-44|3|-27|3		3	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140783805	140783805	C	T	0.4780	295		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1178-648G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron10/19:c.1298-648G>A::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron9/17:c.1178-648G>A::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron10/18:c.1298-648G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267644	0.09907	0.15097,0.06949,0.08970,0.06974,0.19162	829,	13415	137069	-0.0630	0.95			/0.0>0.0/0.0>0.0	COSV56180947	BRAF|0.00|0.00|0.00|0.00|-2|-30|9|-29		6	ARO-16,Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140785535	140785535	T	C	0.9985	659		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+2013A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron10/19:c.1297+154A>G::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron9/17:c.1177+2013A>G::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron10/18:c.1297+154A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267645	0.29838	0.66426,0.18001,0.17420,0.14178,0.30895	10816,	23783	106789	2.8290	21.70			/0.0>0.0/6.6>5.0	COSV56111038	BRAF|0.00|0.00|0.00|0.00|48|3|-33|3		15	20101I_0461_Stephan,Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140785890	140785890	C	T	1.0000	310		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+1658G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron9/19:c.1178-82G>A::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron9/17:c.1177+1658G>A::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron9/18:c.1178-82G>A::	regulatory_region_variant:enhancer	164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267646	0.29827	0.66420,0.18035,0.17319,0.14193,0.30838	10783,	23763	106645	1.7770	13.90			/1.2>1.5/0.0>0.0	COSV56111046	BRAF|0.00|0.00|0.00|0.00|-2|15|16|-31	14617374	13	20101I_0461_Stephan,Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140786488	140786488	C	T	1.0000	231		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+1060G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron9/19:c.1178-680G>A::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron9/17:c.1177+1060G>A::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron9/18:c.1178-680G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267647	0.29833	0.66413,0.18024,0.17317,0.14188,0.30822	10799,	23776	106720	-3.0470	0.00			/4.3>3.9/0.0>0.0	COSV56111057	BRAF|0.00|0.00|0.00|0.00|-20|17|49|-22		11	20101I_0461_Stephan,ARO-16,Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140786713	140786713	A	G	0.4048	620		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+835T>C::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron9/19:c.1177+835T>C::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron9/17:c.1177+835T>C::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron9/18:c.1177+835T>C::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs80191287	0.05678	0.02329,0.05295,0.08359,0.06927,0.11406	287,	8070	143602	0.2610	6.00			/2.9>3.1/0.3>0.0	COSV56285380	BRAF|0.00|0.00|0.00|0.00|40|-8|-17|36		7	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140786943	140786943	T	C	0.3603	358		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+605A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron9/19:c.1177+605A>G::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron9/17:c.1177+605A>G::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron9/18:c.1177+605A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			5S (rRNA)	rs1270193	0.09758	0.14627,0.06876,0.08928,0.06960,0.19118	787,	13278	137344	-0.2320	3.43			/1.9>2.8/6.6>5.6	COSV56180974	BRAF|0.00|0.00|0.00|0.00|1|27|1|-2		4	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140789219	140789219	-	A	0.4286	28		QUAL=42	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1141-1636dup::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1141-1636dup::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron8/17:c.1141-1636dup::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1141-1636dup::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			AluSg (SINE/Alu)	rs201489839	0.11642	0.20338,0.07821,0.11605,0.07058,0.19775	1198,	14657	129423		0.49			/2.9>2.9/0.0>0.0		BRAF|0.00|0.00|0.00|0.00|-20|-38|27|28		6	22023E_0849_Augsburg_Sommer,22096E_0899_Sommer-Follow-up,SomaticAndTreatment,Test_Twist_Exome_Covaris	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140790582	140790582	C	T	1.0000	108		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1141-2998G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1141-2998G>A::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron8/17:c.1141-2998G>A::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1141-2998G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267634	0.29817	0.66411,0.18047,0.17310,0.14181,0.30764	10785,	23778	106738	-2.2880	0.04			/5.2>3.8/0.0>0.0	COSV56111069	BRAF|0.00|0.00|0.00|0.00|-11|48|10|-35		7	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140791458	140791458	C	T	0.3604	788		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+2850G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+2850G>A::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron8/17:c.1140+2850G>A::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+2850G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L2b (LINE/L2)	rs62487920	0.05649	0.02198,0.05293,0.08369,0.06935,0.11411	287,	8018	143506	-0.3700	5.20			/3.1>11.0/0.0>0.0	COSV56285408	BRAF|0.00|0.00|0.00|0.00|-2|-18|-2|31		4	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140792239	140792239	T	C	0.4974	776		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+2069A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+2069A>G::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron8/17:c.1140+2069A>G::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+2069A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L2b (LINE/L2)	rs1267636	0.11179	0.19255,0.07691,0.08993,0.07063,0.19100	1155,	14704	135176	-2.3910	3.72			/4.8>4.0/0.0>0.4	COSV56181027	BRAF|0.00|0.00|0.00|0.00|1|-18|5|-49	14617374,25916409,35076986	5	20101I_0461_Stephan,ARO-16,Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140792611	140792611	T	C	0.4481	1051		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+1697A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+1697A>G::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron8/17:c.1140+1697A>G::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+1697A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L2b (LINE/L2)	rs62487921	0.05667	0.02188,0.05320,0.08365,0.06966,0.11639	292,	8048	143686	0.0220	4.81			/0.0>0.0/0.0>0.9	COSV56285428	BRAF|0.00|0.00|0.00|0.00|4|-2|-37|33		5	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140792749	140792749	A	G	0.4504	393		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+1559T>C::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+1559T>C::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron8/17:c.1140+1559T>C::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+1559T>C::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L2b (LINE/L2)	rs1326918928	0.00001	0.00000,0.00000,0.00000,0.00001,0.00000	0,	1	152263	0.7040	9.51			/0.0>0.0/0.0>0.0		BRAF|0.00|0.00|0.00|0.00|18|3|-46|24		0		0			0	1	0	0 / 0							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140793229	140793229	A	G	0.4379	644		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+1079T>C::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+1079T>C::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron8/17:c.1140+1079T>C::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+1079T>C::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs57620608	0.05666	0.02189,0.05319,0.08359,0.06967,0.11652	293,	8044	143682	0.2470	7.23			/0.0>0.0/0.0>0.0	COSV56285434	BRAF|0.00|0.00|0.00|0.00|44|-21|-23|50		5	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140795742	140795742	C	T	0.3611	36		QUAL=44	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.981-1275G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.981-1275G>A::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron7/17:c.981-1275G>A::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.981-1275G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs62487923	0.05656	0.02187,0.05309,0.08385,0.06943,0.11441	290,	8016	143394	-0.2650	0.38			/3.0>2.2/0.0>0.0	COSV56285442	BRAF|0.00|0.00|0.00|0.00|-2|1|39|43		2	SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140795773	140795773	T	C	1.0000	47		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.981-1306A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.981-1306A>G::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron7/17:c.981-1306A>G::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.981-1306A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1733826	0.96130	0.99086,0.97443,0.99961,0.94077,0.98322	70435,	5521	5893	-1.2190	0.11			/0.0>0.0/0.0>0.0			26148204	0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140795783	140795783	A	C	0.5735	68		QUAL=151	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.981-1316T>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.981-1316T>G::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron7/17:c.981-1316T>G::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.981-1316T>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs75486053	0.04706	0.01306,0.04460,0.01004,0.06544,0.06894	199,	6756	144874	1.3430	8.52			/4.9>3.5/0.0>0.0	COSV56285453	BRAF|0.00|0.00|0.00|0.00|1|-4|1|48		1	SomaticAndTreatment	0			42	825	0	3 / 145							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140796763	140796763	T	C	0.5465	666		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.981-2296A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.981-2296A>G::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron7/17:c.981-2296A>G::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.981-2296A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			MamRep605 (LTR?)	rs1639675	0.09748	0.14549,0.06871,0.09019,0.06971,0.19204	786,	13266	137374	-0.6720	0.38			/0.7>0.0/0.0>0.0	COSV56181035	BRAF|0.00|0.00|0.00|0.00|30|25|1|25	14617374,35076986	6	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140797786	140797786	A	T	0.5269	484		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.980+2576T>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.980+2576T>A::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron7/17:c.980+2576T>A::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.980+2576T>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs73491871	0.11113	0.19217,0.07492,0.08954,0.07015,0.19162	1139,	14637	135293	-0.0140	10.91			/8.2>6.5/0.0>0.0	COSV56181043	BRAF|0.08|0.00|0.00|0.00|16|-17|-27|-17		9	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140799503	140799503	T	C	0.4146	808		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.980+859A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.980+859A>G::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron7/17:c.980+859A>G::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.980+859A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs117763690	0.01572	0.00402,0.00745,0.00019,0.02139,0.03005	21,	2353	149951	-0.8290	0.58			/0.0>0.4/4.6>7.8		BRAF|0.00|0.00|0.00|0.00|-12|26|5|32		1	SomaticAndTreatment	0			14	1143	0	2 / 167							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140800335	140800335	C	T	0.4253	1059		QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.980+27G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.980+27G>A::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron7/17:c.980+27G>A::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.980+27G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40354 [benign DISEASE=not provided,not specified GENE=BRAF];			rs41282721	0.05643	0.02189,0.05301,0.08353,0.06932,0.11353	291,	8006	143610	-0.0360	7.45			/0.0>0.0/0.0>0.0	COSV56078567,COSV56373227	BRAF|0.00|0.00|0.00|0.00|22|27|27|-36	25741868	5	Novartis,SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
chr7	140808137	140808137	A	T	0.4381	210	off-target	QUAL=255	BRAF	intron	BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron4/18:c.609-75T>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron4/19:c.609-75T>A::,BRAF:ENST00000646891.2:intron_variant:MODIFIER:intron4/17:c.609-75T>A::,BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron4/18:c.609-75T>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40344 [benign DISEASE=not provided GENE=BRAF];			rs17695935	0.05640	0.02181,0.05290,0.08385,0.06931,0.11476	288,	8003	143533	3.1020	18.89			/6.8>5.3/0.0>0.0	COSV56078577	BRAF|0.00|0.00|0.00|0.00|-36|-12|-36|-17		4	SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)									1	0
